Umoja Biopharma Appoints Scott Myers as New Chairman
Umoja Biopharma, Inc., the innovative leader in CAR T-cell therapies, has recently elevated Scott Myers to the position of Chairman of its Board of Directors. This strategic change comes as the organization prepares for significant upcoming milestones in its clinical journey.
Leadership Transition to Boost Company Growth
Scott Myers takes over from Dieter Weinand, who will transition to a strategic advisory role, continuing his support for the company's vision. Andrew Scharenberg, the co-founder and CEO, expressed optimism about working with Myers. His extensive background in the biotechnology sector is expected to provide invaluable insights as Umoja aims for new horizons.
Significant Experience in Biotechnology
Myers’ accomplishments are distinguished by his leadership roles at several biotech firms across the Pacific Northwest. His experience as CEO and chairperson during transformative growth periods will be instrumental for Umoja as it navigates through complex clinical challenges. Scharenberg has previously acknowledged Weinand's contributions, indicating a smooth transition in leadership.
Myers' Vision for the Future
In his new capacity, Scott Myers underlined the unique position of Umoja as a frontrunner in CAR-T cell therapies developed through its proprietary technologies. By facilitating clinical trials across various regions, including the first-ever US IND, Myers aims to operationalize these therapies at a greater scale.
Transforming Healthcare Delivery
Myers expressed his enthusiasm for Ukraine Biopharma's transformative potential. The company focuses on improving delivery mechanisms for CAR-T therapies, which could alter the treatment landscape for patients significantly. He believes that with the right strategies, they can harness the full potential of these advanced therapies.
About Umoja Biopharma
Umoja Biopharma, Inc. is committed to developing cutting-edge, off-the-shelf therapeutics that enhance the effectiveness of CAR-T cell therapies, particularly targeting areas in oncology and autoimmunity. Central to its mission is the innovative VivoVec™ gene delivery technology, which empowers patients' immune systems to combat disease more effectively.
State-of-the-Art Facilities and Technologies
The company operates a modern lentiviral vector development and manufacturing facility in Louisville, Colorado. This facility is crucial for producing high-quality therapies aimed at broadening access and improving patient outcomes through innovative immunotherapies.
Our Commitment to Patients
Umoja Biopharma’s approach promises to enhance the accessibility and efficacy of therapeutics, allowing more patients to enjoy healthier lives. They believe that every breakthrough in CAR-T technology contributes positively to patient care globally.
Contact Information
For investors:
Grace Kim
Head of Investor Relations
Email: grace.kim@umoja-biopharma.com
For media inquiries:
Matt Wright
Real Chemistry
Email: mwright@realchemistry.com
Frequently Asked Questions
What is Umoja Biopharma known for?
Umoja Biopharma specializes in developing CAR-T cell therapies aiming to enhance patient outcomes in oncology and autoimmunity.
Who is Scott Myers?
Scott Myers is the newly appointed Chairman of the Board for Umoja Biopharma, with extensive experience in the biotechnology sector.
What is the significance of the board change?
The change aims to leverage Myers’ expertise to guide Umoja through critical upcoming clinical milestones.
What technologies does Umoja Biopharma use?
Umoja utilizes VivoVec™ technology for gene delivery, which enhances the effectiveness of CAR-T therapies.
Where is Umoja Biopharma based?
The company is based in the United States and operates a manufacturing facility in Louisville, Colorado.
